What is the appropriate protocol for initiating estrogen therapy in a transgender female?

How to Start Estrogen in Transgender Females

Initiate estrogen therapy with 17β-estradiol (oral, transdermal, or parenteral) combined with an antiandrogen (spironolactone or cyproterone acetate), targeting serum estradiol levels of approximately 200 pg/mL and testosterone suppression to <50 ng/dL. 1

Pre-Treatment Requirements

Before prescribing hormones, confirm the patient meets eligibility criteria:

• Diagnosis of gender dysphoria/gender incongruence by a mental health professional
• Informed consent documented regarding all risks, benefits, and expected effects
• Age of majority (typically 18 years) or appropriate adolescent protocols
• Medical clearance with baseline labs obtained 1

Critical caveat: Avoid synthetic estrogens, particularly ethinyl estradiol, which carry a 20-fold increased risk of venous thromboembolism and cannot be monitored by serum levels 1. This is a major safety concern that significantly impacts mortality.

Estrogen Formulations and Dosing

Transdermal Estradiol (Preferred for Older Patients or VTE Risk)

• Start with ≤5 mg weekly or 1-2 patches of 0.1 mg/24 hours 2, 3, 4
• Transdermal preparations confer advantages in patients at higher risk for thromboembolic disease 1
• Recent evidence shows most patients achieve target testosterone suppression within 2 months on 1-2 patches of 0.1 mg/24 hours 2
• More rapid testosterone suppression compared to sublingual routes 2

Oral 17β-Estradiol

• Can be given as oral conjugated estrogens or 17β-estradiol
• Current guidelines suggesting 2-20 mg weekly for injectable forms are likely too high 3, 4
• For oral preparations, titrate to achieve target estradiol levels

Injectable Estradiol (Valerate or Cypionate)

• Start at ≤5 mg weekly (subcutaneous or intramuscular) 3
• Recent data shows 3-4 mg weekly achieves physiologic levels in most patients 4
• 78-76% of patients on 3-4 mg weekly achieved estradiol concentrations of 100-357 pg/mL 4
• Lower doses than traditional guidelines prevent supraphysiologic levels 3, 4

Important note: There is no difference in efficacy between once-daily versus twice-daily sublingual estradiol dosing, so pulsed dosing provides no additional benefit 2.

Antiandrogen Selection

Combine estrogen with one of the following:

Spironolactone (Most Common in US)

• Directly inhibits testosterone secretion and androgen receptor binding
• May have additional estrogenic activity 1
• Enhances testosterone suppression: 83.6% achieved testosterone <50 ng/dL on 3 mg estradiol with spironolactone vs 90% on 4 mg 4

Cyproterone Acetate

• Progestational compound with antiandrogenic properties
• Widely used in Europe 1

GnRH Agonists (e.g., Goserelin Acetate)

• Effective in reducing testosterone with low adverse reaction incidence
• Monthly administration 1

Avoid flutamide: Has liver toxicity and unproven efficacy 1

Target Hormone Levels

• Serum estradiol: ~200 pg/mL (mean daily level for premenopausal women) 1
• Serum testosterone: <55 ng/dL (female range) 1
• Note: The commonly cited 100-200 pg/mL range lacks evidence for optimal feminization 5

Monitoring Protocol

First Year (Every 2-3 Months)

• Serum estradiol and testosterone levels
• Complete blood count and liver function tests
• Blood pressure, weight, lipids
• Fasting glucose (if family history of diabetes)
• Prolactin levels (baseline and annually) 1

After First Year (1-2 Times Annually)

• Continue hormone level monitoring
• Cardiovascular risk factor assessment 1
• Prolactin monitoring (biannually after transition period) 1

Timing of blood draws matters: For injectable estradiol, measure levels midway between injections to avoid misleading peaks or troughs 3, 4.

Critical Safety Considerations

Venous Thromboembolism Prevention

• Strongly encourage tobacco cessation - this is non-negotiable for reducing VTE and cardiovascular risk 1
• Transdermal formulations have the most favorable VTE safety profile 6
• Screen for thrombophilia only if personal or family history of VTE 1
• Do NOT routinely monitor D-dimer levels 1
• Routine primary anticoagulant prophylaxis is not recommended for low-risk individuals 6

Avoid Supraphysiologic Dosing

Sustained supraphysiological testosterone or estrogen levels increase adverse reaction risk 1. Recent evidence consistently shows that lower doses than traditionally recommended achieve adequate feminization while minimizing harm 3, 4.

Prolactin Monitoring

Up to 20% may develop hyperprolactinemia with pituitary enlargement, though prolactinomas are rare. If prolactin persistently increases despite stable/reduced estrogen, consider pituitary imaging 1.

Expected Timeline of Effects

Physical changes occur gradually 1:

• Decreased libido/erections: 1-3 months onset, maximum 3-6 months
• Breast growth: 3-6 months onset, maximum 2-3 years (may extend beyond) 7
• Body fat redistribution: 3-6 months onset, maximum 2-3 years
• Decreased muscle mass: 3-6 months onset, maximum 1-2 years
• Skin softening: 3-6 months onset

Quality of Life Considerations

Gender-affirming hormone therapy is associated with significant improvements in mental health outcomes, including reduction in depression, anxiety, and gender dysphoria 8. The physical changes are usually accompanied by improvement in mental well-being 1. These quality-of-life benefits are substantial and medically necessary for many transgender individuals.